Lumida
/PACB
⌘K
Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

PACB
$1.40USD-9.68%-0.15 today

MARKET CAP

442.9M

P/E (TTM)

FWD P/E

DAY RANGE

$1 – $2

52W RANGE

$1
$3

AI Summary

Stalk
StalkMedium

PACB remains in an early Stage 1 consolidation that has just broken above its multi-month range on strong volume, signaling potential transition into a Stage 2 advance. However, price is extended above the rising short-term EMAs and in overbought territory, making immediate execution unfavorable. We will wait for a pullback into the reclaimed resistance zone around the 9/21 EMAs and the 50 SMA for optimal participation in the emerging advance.

  • Spark Next chemistry launch drives strong clinical adoption
  • Consumables revenue rose 6% YoY; clinical consumables up 67%
  • Revised 2026 revenue guidance $155–165M on funding headwinds
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$130.5M$128.3M$200.5M$154.0M$160.0M
YoY %+65.4%-1.7%+56.3%-23.2%+3.9%
P / Sales32.0x13.9x12.1x3.4x3.5x
EV / Sales37.8x20.7x16.4x8.0x8.0x
Gross Profit, Adj.$58.9M$49.0M$52.8M$37.3M$45.8M
YoY %+80.7%-16.7%+7.6%-29.4%+22.8%
Margin %45.1%38.2%26.3%24.2%28.6%
EV / Gross Profit83.8x54.3x62.5x32.9x27.9x
EBITDA, Adj.$-166.6M$-294.4M$-305.7M$-248.6M$-156.4M
YoY %-75.2%-76.7%-3.8%+18.7%+37.1%
Margin %-127.6%-229.5%-152.5%-161.4%-97.8%
EV / EBITDA-29.6x-9.0x-10.8x-4.9x-8.2x
EBIT$-210.4M$-307.2M$-334.5M$-474.3M$-553.9M
YoY %-101.6%-46.0%-8.9%-41.8%-16.8%
Margin %-161.2%-239.4%-166.8%-308.0%-346.2%
EV / EBIT-23.4x-8.7x-9.9x-2.6x-2.3x
Net Income$-181.2M$-314.2M$-306.7M$-309.9M$-546.4M
YoY %-716.3%-73.4%+2.4%-1.0%-76.3%
Net Margin-138.9%-244.9%-153.0%-201.2%-341.5%
EPS (GAAP)-$0.89-$1.40-$1.21-$1.59-$1.82
YoY %-623.5%-57.3%+13.6%-31.4%-14.5%